Developing new drugs for ovarian cancer: a challenging task in a changing reality.
Recent therapeutic and technological advances have profoundly modified the parameters of new drug testing in ovarian cancer. The potential of compounds tested today in this disease therefore needs to be assessed according to this changing reality. Previous treatment with or without cisplatin is the criterion we have applied in our review of the single agent clinical data. Results obtained with older compounds have also been, when possible, reassessed in order to facilitate a comparative interpretation of recent trials. A brief overview of the most recently developed laboratory screening models has been conducted in order to stress their close relationship and their crucial role in future new drug development.
D000818:Animals; D000970:Antineoplastic Agents / Q000627:therapeutic use*; D002460:Cell Line; D002986:Clinical Trials as Topic; D003131:Combined Modality Therapy; D004195:Disease Models, Animal; D004341:Drug Evaluation; D004353:Drug Evaluation, Preclinical / Q000379:methods; D005260:Female; D006801:Humans; D051379:Mice; D010051:Ovarian Neoplasms / Q000188:drug therapy* / Q000601:surgery; D012107:Research Design; D014410:Tumor Stem Cell Assay
D000970:Antineoplastic Agents